(Boursier.com) — Illuminated , a U.S.-based sequencing and array technology giant fueling advancements in life sciences, anticipates fourth-quarter revenue of around $1.075 billion, versus a FactSet consensus of $1.063 billion. The company provided these estimates during a presentation at the JPMorgan Healthcare conference yesterday. The group thus reports preliminary consolidated turnover above expectations, which would bring consolidated turnover for the 2022 financial year to 4.576 billion dollars. For the 2023 financial year, sales are expected between 4.90 and 5.03 billion dollars, which represents a growth in sales of +7 to 10% (FactSet consensus 5.005 billion). Non-GAAP operating margin is expected to be around 8% in 2023, while non-GAAP EPS is expected to be between $1.25 and $1.50.
©2023 Boursier.com